Pioglitazone clinical trials
Also written Actos, AD4833 and BR3006B.
How each study uses Pioglitazone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Pioglitazone studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 15 Jul 1999 · ACTOS · NDA 021073 (FDA, Drugs@FDA)
- European Union
- 11 Oct 2000 · Glustin · EMEA/H/C/000286 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
Studies by the year they started
333 studies that test it; most in 2008 (34)
| Year | Studies |
|---|---|
| 2000 | 4 |
| 2001 | 3 |
| 2002 | 8 |
| 2003 | 16 |
| 2004 | 12 |
| 2005 | 23 |
| 2006 | 19 |
| 2007 | 23 |
| 2008 | 34 |
| 2009 | 27 |
| 2010 | 17 |
| 2011 | 16 |
| 2012 | 11 |
| 2013 | 11 |
| 2014 | 8 |
| 2015 | 8 |
| 2016 | 14 |
| 2017 | 6 |
| 2018 | 12 |
| 2019 | 7 |
| 2020 | 9 |
| 2021 | 7 |
| 2022 | 9 |
| 2023 | 8 |
| 2024 | 7 |
| 2025 | 9 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 72 · Other 264
Takeda (33) · The University of Texas Health Science Center at San Antonio (13) · University of Texas Southwestern Medical Center (7) · Stanford University (6) · The University of Texas Health Science Center, Houston (5) · AstraZeneca (5) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (5) · Tehran University of Medical Sciences (5)
Often tested with
Tested in the same studies.
Metformin (43) · Sitagliptin (12) · Empagliflozin (10) · Dapagliflozin (9) · Alogliptin (6) · Atorvastatin (4) · Glimepiride (4) · Canagliflozin (3)
Related medicines
As reviewed, each with the page that says it.
- One of Hypoglycemic Agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 14, 1 in phase 3
Studies that test Pioglitazone, phase 3 first.
- Jun 2027SGLT2i, Pioglitazone, and Ketone Production in T1DPhase 3 · The University of Texas Health Science Center at San Antonio
- Dec 2026Pioglitazone Therapy Targeting Fatigue in Breast CancerPhase 2 · West Virginia University
- Dec 2026Enhancing PCOS Management for Better Outcomes of Intracytoplasmic Sperm InjectionNot applicable · Beni-Suef University
- Dec 2026Insulin Regulation of Lipolysis and Lipolysis ProteinsEarly Phase 1 · Mayo Clinic
- Dec 2026Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 DiabetesPhase 4 · Seoul National University Bundang Hospital
- Dec 2026A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.Early Phase 1 · Rambam Health Care Campus
- Jan 2027Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)Phase 1/2 · National Institute of Allergy and Infectious Diseases (NIAID)
- Feb 2027Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)Not applicable · The University of Texas Health Science Center at San Antonio
- Mar 2027Quantifying Hepatic Mitochondrial Fluxes in HumansPhase 4 · The University of Texas Health Science Center at San Antonio
- May 2027Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes MellitusPhase 2 · Mayo Clinic
Studies
Open first, then newest update. How each study uses Pioglitazone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 336
- Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 FibrosisRecruitingPhase 4Madrigal Pharmaceuticals, Inc.NCT07848191Written as ACTOS/pioglitazone
- Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)RecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT03109288Written as Pioglitazone
- Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus ParticipantsRecruitingPhase 4The University of Texas Health Science Center at San AntonioNCT05838287Written as Pioglitazone
- Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)RecruitingNot applicableThe University of Texas Health Science Center at San AntonioNCT02969798Written as Pioglitazone
- Quantifying Hepatic Mitochondrial Fluxes in HumansRecruitingPhase 4The University of Texas Health Science Center at San AntonioNCT05305287Written as Pioglitazone
- Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes MellitusRecruitingPhase 2Mayo ClinicNCT06729996Written as Pioglitazone (PIO)
- Bioenergetic Effect of Pioglitazone in CLD-PHRecruitingPhase 2Emory UniversityNCT06336798Written as Pioglitazone 30mg
- SGLT2i, Pioglitazone, and Ketone Production in T1DRecruitingPhase 3The University of Texas Health Science Center at San AntonioNCT07056699Written as Pioglitazone 15 MG and 30mg
- An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard TherapyRecruitingPhase 2Fudan UniversityNCT07117630Written as Pioglitazone (PIO)
- Second STOP After Pioglitazone Priming in CML PatientsRecruitingPhase 2Versailles HospitalNCT02889003Written as Pioglitazone + TKI
- A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO TrialRecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT05946564Written as Pioglitazone (ACTOS®)
- Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or TirzepatideRecruitingPhase 4Stanford UniversityNCT06657209Written as Pioglitazone
- Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset DiabetesRecruitingPhase 3The University of Texas Health Science Center at San AntonioNCT06246799Written as Pioglitazone
- Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation RateRecruitingPhase 4PAEC General Hospital, IslamabadNCT07462065Written as Pioglitazone (PIO) + Clomiphene citrate
- Insulin Regulation of Lipolysis and Lipolysis ProteinsRecruitingEarly Phase 1Mayo ClinicNCT03866408Written as Pioglitazone
- Prevention of Progression of Prediabetes, Obesity and CV RiskRecruitingPhase 1The University of Texas Health Science Center at San AntonioNCT06446531Written as Actos
- Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver DiseaseNot yet recruitingPhase 4Badr UniversityNCT07180745Written as Pioglitazone (PIO)
- Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?Not yet recruitingPhase 4Dasman Diabetes InstituteNCT06922656Written as Pioglitazone 45 mg
- A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)RecruitingPhase 1Boryung Pharmaceutical Co., LtdNCT07083401Written as Pioglitazone 30 mg
- A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)RecruitingPhase 1Boryung Pharmaceutical Co., LtdNCT07083388Written as Pioglitazone 30 mg
See all 336 studies that test Pioglitazone →
Given beside what is tested · 39 — Pioglitazone is usual care or a partner of the new treatment
- A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 DiabetesRecruitingPhase 4Boryung Pharmaceutical Co., LtdNCT06972732Written as Dapagliflozin/Pioglitazone
- A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate CancerActive, not recruitingPhase 1Aragon Pharmaceuticals, Inc.NCT02592317Written as Pioglitazone
- A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic PatientsCompletedPhase 3Astellas Pharma IncNCT01225081Written as Pioglitazone
- Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic ControlCompletedPhase 3University of BasrahNCT06107153Written as Pioglitazone 30mg
- Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 DiabetesCompletedPhase 3Novartis PharmaceuticalsNCT00099853Written as pioglitazone
- A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)TerminatedPhase 4Eli Lilly and CompanyNCT02072096Written as Pioglitazone
- A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian ParticipantsCompletedPhase 1TakedaNCT03501277Written as Pioglitazone
- Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 DiabetesTerminatedPhase 3Novo Nordisk A/SNCT00411892Written as pioglitazone
- Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mgCompletedPhase 1Dong-A ST Co., Ltd.NCT02753803Written as Evogliptin, Pioglitazone, Evogliptin+Pioglitazone
- A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin AloneCompletedPhase 3AstraZenecaNCT01095666Written as Pioglitazone
- A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult SubjectsCompletedPhase 1GlaxoSmithKlineNCT01489943Written as Pioglitazone 15 mg
- Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes MellitusCompletedPhase 3Daiichi SankyoNCT00789750Written as Pioglitazone
- Drug-drug Interaction Study With MDV3100 and a Cocktail of SubstratesCompletedPhase 1Astellas Pharma Europe B.V.NCT01911728Written as Pioglitazone
- A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)CompletedPhase 3Merck Sharp & Dohme LLCNCT01076075Written as Comparator: pioglitazone
- Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)CompletedPhase 3Merck Sharp & Dohme LLCNCT00885352Written as Pioglitazone
- MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00372060Written as Comparator: pioglitazone
- Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00086515Written as Pioglitazone
- Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 DiabetesCompletedPhase 3NovartisNCT00138554Written as pioglitazone
- GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of PioglitazoneCompletedPhase 3SanofiNCT00763815Written as Pioglitazone
- Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate CancerCompletedPhase 2Novartis PharmaceuticalsNCT00427999Written as pioglitazone
Showing 20 of 39.
As the comparator · 43 — what is tested is compared with Pioglitazone
- Enavogliflozin vs. Pioglitazone on Glucose and AtherosclerosisRecruitingPhase 4Seoul National University Bundang HospitalNCT06399835Written as Pioglitazone
- Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes MellitusRecruitingPhase 3EMSNCT05028140Written as PIOGLITAZONE
- Adipose Tissue Heterogeneity and Its Link to Type 2 DiabetesRecruitingNot applicableKarolinska InstitutetNCT05501483Written as Pioglitazone 45 mg
- Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on MetforminTerminatedPhase 2Gilead SciencesNCT00814372Written as Actos
- A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes MellitusCompletedPhase 2AmgenNCT01028963Written as pioglitazone
- Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic SteatohepatitisCompletedPhase 2Cairo UniversityNCT05254626Written as Pioglitazone 30 mg
- Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes MellitusTerminatedPhase 2Charles Drew University of Medicine and ScienceNCT02303405Written as Pioglitazone
- Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian SyndromeCompletedPhase 2Khyber Medical University PeshawarNCT04867252Written as Metformin (500 mg Twice a day), Pioglitazone (15 mg Twice a day)
- Study of Rivoglitazone in Type 2 Diabetes MellitusCompletedPhase 3Daiichi SankyoNCT00484198Written as Pioglitazone
- Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver DiseasesCompletedPhase 4Dong-A ST Co., Ltd.NCT03910361Written as Pioglitazone
- Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian SyndromeCompletedEarly Phase 1Khyber Medical University PeshawarNCT03117517Written as Metformin, Pioglitazone
- Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During RamadanCompletedPhase 4University of LeicesterNCT02694263Written as Pioglitazone
- Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 DiabetesCompletedPhase 4Pusan National University HospitalNCT01882907Written as Pioglitazone
- Study of NGM313 in Obese ParticipantsCompletedPhase 1NGM Biopharmaceuticals, IncNCT03298464Written as Pioglitazone
- A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)CompletedPhase 2Merck Sharp & Dohme LLCNCT01217073Written as Pioglitazone
- Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)CompletedPhase 2GlaxoSmithKlineNCT00500331Written as pioglitazone
- Response To Oral Agents in Diabetes (ROAD)- Pilot StudyCompletedPhase 4University of DundeeNCT00780715Written as Pioglitazone
- Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and PioglitazoneCompletedPhase 4Yonsei UniversityNCT02875821Written as metformin with pioglitazone
- MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)CompletedPhase 3Merck Sharp & Dohme LLCNCT00532935Written as Comparator: pioglitazone
- A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)CompletedPhase 3Merck Sharp & Dohme LLCNCT01076075Written as Comparator: pioglitazone
Showing 20 of 43.
Codes
What other systems call Pioglitazone · ClinicalTrials.gg INT006661
- MeSH (NLM) D000077205PioglitazoneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) X4OV71U42SPIOGLITAZONEConfirmed FDA, NLM, Wikidata
- RxNorm 33738Confirmed FDA, Wikidata
- Wikidata Q417765(RS)-pioglitazoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71633PioglitazoneOne source FDA
- DrugBank DB01132One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077205 | Pioglitazone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | X4OV71U42S | PIOGLITAZONE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 33738 | — | Confirmed FDA, Wikidata |
| Wikidata | Q417765 | (RS)-pioglitazone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71633 | Pioglitazone | One source FDA |
| DrugBank | DB01132 | — | One source Wikidata |
Also registered as pioglitazone hydrochloride (UNII JQT35NPK6C · RxNorm 259319).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.